Aileron Therapeutics Rebrands as Rein Therapeutics, Focuses on Fibrosis Therapies
Key Insights
Aileron Therapeutics has rebranded to Rein Therapeutics, signaling a sharpened focus on developing treatments for orphan pulmonary (search) and fibrotic diseases (search).
Rein Therapeutics' lead candidate, LTI-03, is set to enter a Phase 2 clinical trial in the first half of 2025 for the treatment of idiopathic pulmonary fibrosis (search) (IPF).
The company's stock will trade under the new ticker symbol "RNTX" on Nasdaq starting January 13, 2025, marking a new chapter for the company.
Rein Therapeutics, formerly known as Aileron Therapeutics, announced its rebranding, reflecting the company's dedication to creating innovative therapies for pulmonary (search) and fibrotic diseases (search). The company's shares will commence trading on Nasdaq under the ticker symbol "RNTX" on January 13, 2025.
The rebranding underscores Rein Therapeutics' commitment to addressing the unmet needs of patients with fibrotic conditions. The company's pipeline features two Phase 2-ready clinical assets, highlighting its focus on orphan pulmonary (search) and fibrosis indications.
LTI-03: Advancing Towards Phase 2 for IPF
Rein Therapeutics' lead candidate, LTI-03, a Caveolin-1 (search) related peptide, is poised to enter a Phase 2 clinical trial in the first half of 2025 for the treatment of idiopathic pulmonary fibrosis (search) (IPF). This follows positive topline data from Cohort 2 of a Phase 1b trial, which assessed the safety, tolerability, and exploratory biomarkers of inhaled high-dose LTI-03 (5 mg BID) in IPF patients. The Phase 1b data showed statistically significant changes in four biomarkers and dose-dependent effects in five biomarkers, indicative of active pharmacodynamics and a favorable safety profile.
LTI-01: Addressing Loculated Pleural Effusions
LTI-01, Rein's second asset, is a first-in-class therapy for loculated pleural effusions (search) (LPEs). It is Phase 2b-ready and has been granted Orphan Drug Designation in both the U.S. and E.U. for pleural empyema (search), as well as Fast Track Designation in the U.S.
Leadership and Strategic Objectives
Brian Windsor, Ph.D., President and Chief Executive Officer of Rein Therapeutics, stated, "Our rebrand to Rein Therapeutics reflects our unwavering commitment to address the critical needs of underserved patients with fibrotic diseases (search). This new chapter for the Company underscores our focus on reining in fibrosis and advancing our pipeline of novel candidates. We look forward to the initiation of a Phase 2 clinical trial for our lead candidate, LTI-03, in the first half of this year, aiming to bring hope to those affected by idiopathic pulmonary fibrosis (search)."
In March 2024, Brian Windsor was appointed CEO, solidifying the company's focus on therapies for orphan pulmonary (search) and fibrosis indications. In May 2024, Rein Therapeutics completed a registered direct offering, raising approximately $17.7 million to support its clinical programs.